

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 2, 2022, Context Therapeutics Inc. ("the Company") held its Annual Meeting of Stockholders. As of April 4, 2022, the record date for the Annual Meeting, there were 15,966,053 shares of Company common stock issued and outstanding and entitled to vote on the proposal presented at the Annual Meeting, of which 9,161,941, or approximately 57.38%, were present or represented by proxy, which constituted a quorum. The holders of shares of Company common stock are entitled to one vote for each share held. Set forth below are the final voting results for the proposal submitted to a vote of the Company's stockholders at the Annual Meeting, which was described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 4, 2022.

Proposal 1. Ratification of Selection of Independent Registered Public Accounting Firm

The Company's stockholders ratified the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022. The voting on this proposal is set forth below:

	<u>For</u>	<u>Against</u>	<u>Abstentions</u>	<u>Broker Non-Votes</u>
Ratification of CohnReznick LLP	9,144,524	8,877	8,540	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 3, 2022

Context Therapeutics Inc.

By: /s/ Martin Lehr

Name: Martin Lehr

Title: Chief Executive Officer